# Prelude

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prelude

- Industry: Medical Devices & Equipment
- Headquarters: Laguna Hills, US
- Website: www.preludedx.com
- Total disclosed funding: $9.3M
- Latest round: Series F (Jan 31, 2022)
- Investors on record: 1

## About

Prelude Corp., founded in 2009 and based in Laguna Hills, US, focuses on innovative diagnostic solutions for breast cancer, specifically enhancing treatment decisions for ductal carcinoma in situ (DCIS) patients.Prelude Corp. specializes in precision medicine through the development of diagnostic tests for cancer treatment. The company was founded in 2009 in Laguna Hills, US, and has completed a total of 3 deals. Its latest funding round was a Series F, where it raised USD 9.28 mn on January 31, 2022, led by Evidity Health Capital. Dan Forche serves as the CEO, guiding the company’s vision and operations.PreludeDx specializes in the development and commercialization of innovative diagnostic tests for breast cancer, specifically targeting patients diagnosed with ductal carcinoma in situ (DCIS). The company's flagship product, DCISionRT, is a biomarker test that identifies distinct risk profiles among DCIS patients and predicts their benefit from radiation therapy. This test enables healthcare providers to tailor treatment plans based on individual recurrence risks, helping to determine which patients can safely forgo radiation therapy. PreludeDx serves a diverse client base that includes oncologists, healthcare institutions, and cancer treatment centers primarily in the United States, with its offerings expanding into international markets as awareness and demand for precision medicine grow. The company aims to improve patient outcomes by delivering personalized treatment options that minimize unnecessary interventions.PreludeDx generates revenue through the provision of its diagnostic services, particularly the DCISionRT test. Transactions typically occur on a direct-to-consumer basis, where healthcare providers order the tests for their patients, and insurance reimbursement processes often facilitate payment. The company establishes partnerships with healthcare organizations to enhance adoption and integration of their diagnostic solutions into existing treatment protocols. Pricing structures for the DCISionRT test reflect its proprietary nature, and the firm utilizes a B2B model, collaborating with medical institutions to streamline the ordering and delivery of its services. Revenue is generated through both individual test orders and potential subscription models for ongoing access to updated diagnostic insights, thereby reinforcing its commitment to improving cancer care.In January 2022, Prelude Corp. raised USD 9.28 mn in venture funding led by Evidity Health Capital, with the investment aimed at accelerating the growth and development of its precision medicine portfolio. The company is focused on expanding its offerings, specifically aiming to introduce new diagnostic tests and enter additional international markets to enhance patient access by 2025.

## Funding rounds

- Series F, Jan 31, 2022, $9.3M — Evidity Health Capital

## Investors

- Evidity Health Capital (https://capitalatlas.ai/funds/evidity-health-capital) — Series F